About the forum

Following the success of last year’s event, we are delighted to announce Practical Law’s 2nd Life Sciences Law Forum will take place at the Langham Hotel, London on 4-5 March 2014. We listened to your feedback in developing the 2014 agenda; secure more GCs, re-run the champagne round tables and stay international.

NEW FOR 2014!

Learn practical strategies in our EIGHT key headline themes, including: competition and IP, regulation and ethics, litigation, M&A and transactions and many more...

  • Prepare for the new clinical trials Module 6 guidelines.
  • Hear best ways forward to enforce IP rights in the EU.
  • Develop effective compliance procedures to mitigate reputational risk.
  • Learn how to stay innovative: the US and how the America Invents Act is working.
  • Discover more: updates on SPC litigation, EU investigations into patent settlement agreements and its impact on generic market entry.

And don’t miss our special feature: discover best practice ways to improve interaction with different parts of your business in our Commercial Clinic: the role of GCs in today’s life sciences industry.


Network at our champagne country focus roundtables on the ‘NEW’ emerging markets (TURKEY, MENA, ARGENTINA, INDONESIA, RUSSIA, CHINA and IRELAND)

Last year we focused on legal trends in the life sciences industry. Continuing with this broad structure, next year’s programme will also focus on commercial issues to help align your strategy to current business needs.

With our diverse panel sessions including perspectives from in-house, private practice and the regulators, you will be sure to gain a complete breakdown of life sciences industry trends at a global level.

If you have an interesting story to share and would like to join our speaker faculty, then please do let me know.

We look forward to seeing you on 4-5 March 2014.

Yours faithfully,

Krina Amin
Conference Producer

Day 1

Time Details
9.45am - 10.00am

Open and welcome from chair

Jane Sinclair, Head of International Legal, and Global Privacy, AbbVie Pharmaceuticals

10.00am – 10.30am

Introduction: Setting the global scene

  • Key commercial and legal developments in the global life sciences industry.
    • Standards, case law and technologies?
    • Restructuring your operations effectively to adapt your business model to the current climate and needs of the future.


10.30am – 11.00am

Coffee Break

11.00am – 11.45am


SPCs – what can be protected?

  • Hot ticket items in EU case law.
    • What level of protection do SPCs provide?
  • What may happen looking forward?


11.45am – 12.45pm

New developments within EU competition: parallel imports

  • Managing the life cycle of a pharmaceutical product:
    • Repercussions of Losec on the industry and setting new industry standards.
    • EU investigations into patent settlement agreements and impact on generic market entry.
  • Distribution strategies and managing the impact on parallel trade.



12.45pm – 1.30pm


1.30pm – 2.30pm

Interactive workshops

Workshop 1: Theme 2: Commercial clinic: the role of GCs in today’s life sciences industry

  • Best practice ways to improve interaction with different parts of your business.
  • Handling conflicts between legal and management.

MARLA S. PERSKY, Senior Vice President, General Counsel & Secretary, BOEHRINGER INGELHEIM
JANE SINCLAIR, Head of International Legal, and Global Privacy, AbbVie Pharmaceuticals



3.00pm – 3.45pm

Managing global compliance investigations and risk globally

  • Practical issues, global trends and managing risk – how to structure your strategy.
  • Corruption in China – how do we move forward?
  • Key issues to think about in Latin America.







4.00pm – 5.30pm

Theme 4: Doing business in the BRICs and beyond

Country-focus roundtables on the 'new' emerging markets. With increased regulatory enforcement, stagnant growth and emerging competition, doing business in the traditional BRIC economies has presented its challenges. Discover younger, more promising ventures in untapped markets like Turkey, MENA, Argentina and Indonesia.

  • Argentina: CARLOS LANARDONNE, Legal Director and Country Compliance Head, NOVARTIS
  • Ireland: ROBERT O'SHEA, Partner, MATHESON


Day 2

Time Details
8.25am - 9.10am

Breakfast Roundtable hosted by Baker & McKenzie

9.10am - 9.15am

Open from chair

9.15am - 9.45am

Opening session from Deloitte

9.45am – 10.30am

Theme 5: IP strategies, procedures and innovation

Financial and strategic issues surrounding the unitary patent and Unified Patent Court and attitudes in key Member States

  • The preparatory committee – the big issues.
  • How will it work in practice
  • Workable strategies for generics and patent holders and the impact of multiple actions on your business.
    • Financial impact: costs for renewal, setting up, opting out.
    • How much disclosure is necessary?

CHRIS MERCER, Immediate Past President, Chartered Institute of Patent Attorneys
ADAM COOKE, Partner, DLA Piper

10.30am – 11.15am

IP enforcement in the EU – best ways forward?

  • Seeking preliminary injunctions and other means of patent enforcement.
  • Application of the new customs regulation in patent enforcement and dealing with goods that infringe trademarks and other IP.

EWAN JOHN NETTLETON, Senior Patent Counsel, Oncology, NOVARTIS

11.15am - 11.30am

Morning coffee break

11.30am – 12.30pm

Theme 6: Governance and government intervention

Workshop 1: All eyes on America: the repercussions of the Sunshine Act around the globe Workshop 2: UK challenges in gaining market access for new drugs
  • Lessons from the impending disclosure in America
  • The global clash between industry codes and national legislation
  • Managing cross-border relationships
  • The effect of transparency on physician relationships
  • The practical impact of transparency: meaningful information or data overload?



  • Defining market access.
  • What are the hurdles in gaining marketing authorization?
  • A discussion of UK specific pricing and reimbursement challenges facing the life sciences industry:
    • the ongoing PPRS negotiations and how will this translate in practice?
    • VBP discussions and implications.
    • impact of the new NHS commissioning landscape.


12.30pm – 1.30pm

Pricing and reimbursement strategies across Europe

  • Dealing with the commercial impact of reduced drug prices and pressure on margins from public health authorities
  • Competition issues: the impact on parallel imports
  • Knock on effect of deal flow activity for generics in the market
  • Practical implications on health authorities



Closing Comments and Lunch​.

This programme is subject to change.


Javier Rodriguez

Javier Rodriguez

General Counsel, Reckitt Benckiser Pharmaceuticals Inc.

Javier joined the company as General Counsel in 2011, where he is responsible for global legal affairs and compliance. Prior to taking on this role, he spent four years as Senior Counsel with Reckitt Benckiser LLC. His previous experience includes in-house counsel positions with Bayer Healthcare LLC and Berlex Laboratories Inc.

Ewan Nettleton

Ewan Nettleton

Senior Patent Counsel, Oncology, Novartis Pharma AG

Ewan is a Senior Patent Counsel at Novartis Pharma AG in Switzerland where he works on global pharmaceutical litigation projects. This involves managing IP and related litigation in a wide range of jurisdictions. Prior to joining Novartis in September 2010, Ewan was an associate at Bristows in London specializing in IP law with an emphasis on litigation. Ewan is a qualified UK solicitor (since September 2002), and has an MA in chemistry and a DPhil in protein chemistry from Balliol College, Oxford as well as a Diploma in Intellectual Property Law and Practice from Bristol University. He is also a member of the Royal Society of Chemistry.

Marla Persky

Marla S. Persky

Senior Vice President, General Counsel & Secretary, BOEHRINGER INGELHEIM, US

Marla Persky enjoyed a long and distinguished career as the General Counsel of two pharmaceutical companies. In December 2013, Ms. Persky retired as Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim USA where she oversaw a department of over 75 individuals and was a member of the U.S. business executive management team and Boehringer’s Global Legal Management Team. Prior to joining Boehringer Ingelheim, Ms. Persky spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. During her legal career, Ms. Persky managed global legal services, was General Manager of an international medical device business, led international crisis management teams, acquired and integrated international businesses, and designed/implemented legal strategies to manage global mass torts.

In January of 2014, Marla launches WOMN LLC, a company dedicated to helping women succeed in the private practice of law by increasing their knowledge of and acuity with the “business of law.” Throughout her professional life, Ms. Persky has had the opportunity to understand and practice business principles that lead to personal and company success. Through years of mentoring, she has shared her experience and observations with other attorneys and professionals to assist them in building valued, integrated legal departments, career development and business excellence.

Carlos Lanardonne

Carlos Lanardonne

Legal Director and Compliance Head, NOVARTIS, ARGENTINA

Mr. Carlos Lanardonne obtained his Law Degree at the University of Buenos Aires, Argentina. Has an LLM in Law & Economics from the Torcuato Di Tella University. He currently heads the Legal & Compliance Department at Novartis in Argentina, Uruguay, Paraguay and Bolivia. In his position, he's in charge of implementing the overall Legal Strategy and the Compliance and Privacy Programs for all Novartis' divisions operating in these countries. Mr. Lanardonne leads the Intellectual Property Committee at CAEMe (the local Pharma Trade Association) and is a full member of the Legal and Compliance Committees at this chamber and also at the American Chamber located in Buenos Aires, Argentina.

Matthew Frankel

Matthew Frankel

Legal Director Europe, RANBAXY EUROPE

Matthew Frankel has been Ranbaxy Laboratories Limited's European Legal Director since December 2006. Prior to joining Ranbaxy, he spent five years with BTG plc, a UK based specialty pharmaceutical company. He began his private practice career in 1994 at Bristows in London, specializing in patent litigation, and then moved to take up a role in Baker & McKenzie's IP department. Matthew is a UK qualified solicitor and has a MA in Natural Sciences from Christ's College, University of Cambridge. Ranbaxy is a global pharmaceutical company, headquartered in India, which serves customers in over 150 countries.

Funke Abimbola

Funke Abimbola

Managing Counsel, ROCHE

As Managing Counsel for Roche UK, Funke heads up and manages the legal team supporting Roche's pharmaceutical and commercial operations in the UK, Ireland, Malta and Gibraltar. Funke is also Data Privacy Officer for the UK pharmaceutical business with responsibility for ensuring data protection law compliance.

Having initially qualified and practised as a corporate solicitor in the City, Funke worked for a couple of regional firms before joining Roche in January 2012. Roche is the world's largest biotech company.

Funke is recognised as an expert in a number of areas of law including corporate/M&A law (Chambers' legal directory) and commercial law (Legal 500 directory). She won the Association of Women Solicitors' in-house award for 2012 and featured as a leading lawyer in the life sciences/healthcare sector in Legal Business magazine's GC Powerlist for 2013. Funke was also short-listed for Legal Businesswoman of the year (Law Society Excellence Awards 2012) and Legal Counsel of the year (British Legal Awards 2012).

Her team of 5 lawyers advise the business across a broad range of issues including commercial law, competition law, intellectual property, employment, data protection and corporate compliance matters. The team were recent finalists for In-house team of the year (Legal Business Awards and Halsburys' Legal Awards).

Angel Molina

Angel Molina

Senior Counsel, Baxter

Lead the Legal strategies for all Baxter-Gambro Renal business initiatives in Latin America including regional business projects, litigation cases (Antitrust, Commercial, Labor, Administrative and Criminal), negotiation and drafting all types of private and government contracts, market access initiatives and legal lobbing activities with government agencies and healthcare institutions.

Manage Baxter-Gambro inside counsels work in LATAM.

Manage and control of outside counsels Legal strategies in all the matters entrusted to them.

Support to LATAM Compliance function performing Compliance trainings (FCPA, Baxter's Code of Conduct, Interaction with Healthcare Professionals, Third Party Policy) for employees.

Member of LATAM Baxter-Gambro Compliance Committee, in charge of supervising and enforcing Baxter's compliance policies and code of conduct.

Neil O’May

Neil O'May

Partner, Norton Rose Fulbright

Neil O'May joins Norton Rose Fulbright with over 20 years experience in business, corporate and white collar crime. He has acted in a wide range of corporate criminal cases including corporate manslaughter, insider dealing, market abuse, fraud and tax. His particular area of expertise is anti-bribery and corruption. He has experience in acting for companies and individuals in SFO investigations and prosecutions for bribery and corruption across multiple jurisdictions including the US and EU. He acted in the Innospec, Mabey and Johnson and Securrency investigations and prosecutions by the SFO of the companies, board directors and senior managers. His experience covers all aspects of anti-bribery work from internal investigations, through SFO, OFT and Police investigations, to prosecutions, jury trials and appeals. He has also been involved in advising in relation to an OFT investigation into an alleged criminal cartel and an SFO investigation into price fixing in the pharmaceutical sector. He regularly advises companies on bribery issues following whistle-blower allegations, his focus being on managing the internal investigation and advising on dealing with the regulators and prosecution authorities. Neil recently spoke on on a platform on Deferred Prosecution Agreements with Mr Dominic Grieve QC MP, the UK Attorney General.

Paul Melling

Paul Melling

Partner, Baker and Mckenzie

Paul Melling is an English solicitor who has lived and worked in Russia for over 24 years and is the founding partner of Baker & McKenzie's Moscow and Almaty offices.

Paul is Honorary Legal Adviser in Russia to the Association of International Pharmaceuticals Manufacturers (AIPM), Honorary Legal Adviser to the Russo-British Chamber of Commerce and is a member of the Chamber's Advisory Council.

He is founder of the Russia/CIS pharmaceutical and healthcare practice and is head of our CIS office's Compliance Practice Group. He is also a member of the Steering Committees for both Baker & McKenzie's EMEA Pharmaceutical & Healthcare Practice Group and our EMEA Compliance Practice Group.

In 2009 Mr. Melling received the Distinguished Service Award from AIPM for "Outstanding Contribution to the Development of the Russian Pharmaceuticals Market".

Montserrat Llopart

Montserrat Llopart

Partner, Baker and Mckenzie

Montserrat Llopart has extensive experience in pharmaceutical and healthcare law, as well as competition, acquisitions and commercial law. She is head of the Firm's Life Sciences Practice Group in Barcelona and has been recognized by top legal directories including PLC Which Lawyer? and Chambers. She is also a member of the Steering Committee for Baker & McKenzie's EMEA Pharmaceuticals & Healthcare Practice Group.

Montserrat has acted for many renowned corporations in the pharmaceutical and health sector in sectorial regulatory, compliance and commercial issues, as well as competition law, governmental contracts, acquisitions and general commercial matters.

She has considerable experience in compliance advice, such as forensic audits, drafting of codes of professional ethics or advising on advertising and promotion of medicines and medical devices. She has also drafted a wide range of agreements related to the pharmaceutical field. These last include license and distribution agreements and the sub-contracting of clinical trials, R&D and manufacturing activities.

Bonella Ramsay

Bonella Ramsay

Partner, Global Co-Chair Life Sciences Sector, EMEA, DLA Piper

Bonella Ramsay is co-chair of DLA Piper's Global Life Sciences Sector responsible for the EMEA region. She has particular expertise advising on intellectual property, contractual and regulatory matters for the life sciences sector and has many years of experience advising specialty biopharma and medical device companies wishing to expand their operations and presence in Europe. She advises clients across the life cycle of their products and product development and has led many multi-jurisdictional projects, including in relation to the roll-out of clinical programmes for biopharma clients.

As an intellectual property specialist Bonella is involved in IP rights management and strategy for a diverse and international client base as well as structuring and negotiating the exploitation of those rights. She is experienced in drafting and negotiating a wide range of specialist IP and commercial agreements including R&D and collaboration agreements, joint ventures and strategic alliances, patent and other IP licenses, franchise agreements, manufacturing, distribution, supply, early access and co-promotion contracts. Bonella also has experience in advising on business process outsourcing/off-shoring projects for life sciences clients including in relation to IT/IS services, clinical services, clinical data processing, drug safety and other key regulatory-driven functions.

Bonella is highlighted as a leading individual in IP in Legal Experts 2012.

Jane Sinclair

Jane Sinclair

Head of International Legal, and Global Privacy, AbbVie Pharmaceuticals

Jane Sinclair has more than 25 years experience as an international corporate lawyer in both emerging and mature markets across Asia, Europe and the US in the FMCG and pharmaceutical/medical device sectors. For the last six years, she has been Region Counsel for the multi-billion dollar European division of Abbott, moving into AbbVie Biopharmaceuticals when the researched based division of Abbott was spun off at the start of 2013. She has direct responsibility for the creation and execution of legal strategies required to develop product, and geographical, markets whilst protecting the company’s existing market position. She works closely with pan-regional teams to create novel legal solutions as they wrestle with the rapidly developing biosimilars and generic drug industry. Her recent focus has been on the increased role of regulators, and increasing government controls, as they seek to maximise their dwindling public health budgets. She has direct experience of running large multi-national teams with considerable success, and is held in high regard by her team and officers of the company.

Michael Finn

Michael Finn

Associate, Matheson

Michael is a Senior Associate in the Healthcare Team and Commercial Litigation and Dispute Resolution Department at Matheson. Michael advises clients in relation to the regulation of medicinal products and medical devices in Ireland, and has built up a strong expertise in navigating clients through interactions with regulators, including assisting multinational pharmaceutical sector clients in resolving regulatory impasses. Michael also represents clients in regulatory investigations and criminal prosecutions. He advises clients in relation to pricing and reimbursement issues for products supplied under Ireland's state-sponsored community drugs schemes and he has acted for both public and private sector clients in litigation concerning reimbursement issues.

Michael's practice also focuses on mergers and acquisitions in the healthcare sector, and he advises leading global pharmaceutical companies on acquisitions and divestitures of Irish companies and assets. Michael has substantial experience representing clients in the defence of complex and high value medical malpractice claims, and he regularly represents medical practitioners in the defence of regulatory complaints before the Medical Council and other regulatory bodies. Michael has over 10 years of experience across the entire spectrum of Alternative Dispute Resolution, from initial claim risk assessments and devising settlement strategies through to mediation, conciliation and arbitration. He also advises extensively on judicial review proceedings, with a particular focus on actions to challenge decisions taken by healthcare regulatory bodies.

Nicole Reichman

Nicole Reichman

General Counsel – Europe, Otsuka Pharmaceutical Europe, UK

Nicole is currently the European General Counsel for global Japanese Pharmaceutical R&D company Otsuka Pharmaceutical. Having started her legal career in South Africa and relocated to the UK in 2001, Nicole is dual qualified with over 17 years of post-qualified experience in a range of private practice and in-house roles.

Since moving into the pharmaceutical industry in 2007, Nicole has developed specialist industry knowledge and supported and advised Otsuka Europe on various UK and European legal and compliance matters. Nicole has recently taken on the dual role of European Compliance Officer and currently chairs the European Compliance Committee. She is in the process of establishing a pan-European Compliance Programme for Otsuka, including the introduction and implementation of anti-corruption, whistle-blowing and data protection policies and compliance training programmes across the region. Nicole continues to build upon these successes to lead Otsuka to becoming a European leader in Compliance.

Melanie Thill Tayara

Melanie Thill Tayara

Partner, Norton Rose Fulbright

Mélanie Thill-Tayara heads the competition and antitrust practice of the global legal practice Norton Rose Fulbright LLP in Paris and its life sciences and healthcare industry group in EMEA. She is recognised for her litigation and strategic skills and for her pragmatic and business-oriented approach to law. In the life sciences area, she represents a wide range of leading pharmaceutical and medical devices companies. Among others, she has assisted various laboratories with respect to the implementation of quota systems and reorganisation of their distribution schemes and in the subsequent judicial actions these systems have generated. She has also represented leading pharmaceutical companies in the field of abuse of dominant position further to actions initiated by generic companies. She has assisted several groups during (and further to) dawn raids conducted by the competition authorities, leading in some cases to total or partial cancellation of the inspection. She has also assisted clients in cross-border investigations relating to anti-kickback rules.

Robert O'Shea

Robert O'Shea

Partner, Matheson

Robert is a partner in the Corporate Department at Matheson. He is head of the firm's International Business Group and co-head of the firm's US Business and Inward Investment Groups. Robert practises corporate law focusing primarily on the area of inward investment, international corporate reorganisations, post-acquisition integration and consolidation projects, spin-off transactions, cross-border mergers and acquisitions, joint ventures, general commercial contracts and corporate governance and compliance. Earlier in his career, Robert spent a year in-house with a US pharmaceutical company, and he currently works with many of the world’s leading Life Sciences companies.

Robert has extensive experience in leading multi-jurisdictional transactions and has advised in relation to some of the largest inward investment and restructuring projects in Ireland. In particular he has extensive experience drafting and advising on the legal documentation associated with cross-border restructurings and inward investment projects and the complex legal issues that can arise in re-organisation projects.

Chris Mercer

Chris Mercer

President, Chartered Institute of Patent Attorneys

Chris is the current President of CIPA and has been a member of the council of CIPA and its Patents Committee for a number of years. He is a past President of epi. He is a member of SACEPO and of FICPI's Biotechnology Committee. In the past few years, he has been following closely the developments in the European patent and Court systems and has been involved in providing input to the UK Government.

Chris retired in 2010 following a long and successful career at Carpmaels & Ransford and now acts as a consultant to Carpmaels. Chris mainly handles biotechnological and chemical subject-matter but also handles light mechanical subject-matter. His practice is mainly before the European Patent Office in which he has been responsible for a large number of applications and oppositions. He has argued orally before numerous Opposition Divisions and Boards of Appeal and has argued successfully before the Enlarged Board of Appeal. He has been deeply involved in High Court litigation and litigation in Germany and The Netherlands. He is a Patent Attorney Litigator.

Tom Thraya

Tom Thraya


Tom Thraya is a founding partner of the Firm’s Abu Dhabi, Dubai and Doha offices. He is the head of the UAE Corporate and Commercial Practice and is primarily based in Dubai, although he splits his time between the Abu Dhabi and Doha offices. Mr. Thraya has worked in the region for more than seven years (including a year with Legal Advisors in association with Baker & McKenzie Limited in Saudi Arabia working mainly on large private equity/M&A engagements in 2007/2008). He is a fluent Arabic speaker and reader. Prior to joining Baker & McKenzie’s Chicago office in January 2005, Mr. Thraya worked as a corporate and securities associate at Mayer Brown in Chicago from 2001.

Practice Focus

Mr. Thraya advises both private and public clients in the areas of cross-border and domestic mergers, acquisitions, divestitures, international and domestic joint ventures, private equity and global corporate reorganizations. He also advises clients on international and domestic commercial agreements — including licensing, supply, distribution and logistics arrangements — and provides general corporate and commercial counselling. Mr. Thraya also has an international geographic focus on the Middle East, with particular emphasis on Saudi Arabia, the United Arab Emirates, Qatar and Iraq, and plays a key role in the Firm’s North American Middle Eastern Initiative and Practice Group.

Sergey Patrakeev

Sergey Patrakeev

Counsel, Co-Head of Pharmaceuticals Industry Practice, LIDINGS

Sergey Patrakeev is a Counsel in Lidings' Corporate and M&A practice and Co-Head of Pharmaceuticals Industry practice in the firm’s Moscow office. Sergey specializes in advising foreign business on all aspects of corporate law. His expertise covers comprehensive legal support of daily business activities of the pharmaceutical companies including interactions with state authorities, contractual work, interactions with medical representatives, tax and customs regulation, compliance, and dispute resolution matters. The 2013 edition of a prominent international directory The Legal 500 EMEA recognizes Sergey Patrakeev as "very knowledgeable in matters relating to the pharmaceuticals industry".

Karolyn Fletcher

Karolyn Fletcher

Legal Director, Bristol-Myers Squibb Pharmaceuticals Limited

Karolyn Fletcher joined Bristol-Myers Squibb in 2009, where she is currently Legal Director for the UK and Ireland, advising on a wide range of commercial, regulatory, competition and market access issues relating to pharmaceuticals. In July 2013, Karolyn was unanimously re-elected for a third term as Chair of the ABPI's Legal Expert Network. Previously, Karolyn was Pfizer's UK Legal Director. In her 15 years at Pfizer, she advised on issues affecting all parts of the company, including its R&D, manufacturing, Animal Health, Consumer and Pharmaceutical divisions. Karolyn trained, qualified and worked as a Company/Commercial Associate at Allen & Overy before joining Pfizer.

Jeffrey Campbell

Jeffrey Campbell

Managing Principal, Porzio, Brombery & Newman

D. Jeffrey Campbell is the Managing Principal of Porzio, Bromberg & Newman P.C. His law practice is concentrated in Porzio's Life Sciences Compliance and Commercialization Department. Mr. Campbell is also the President and CEO of the firm's subsidiaries – Porzio Life Sciences, LLC and Porzio Governmental Affairs, LLC. He sets the strategic goals of the companies and is actively involved in their management, growth and progress. For Porzio Life Sciences, he has primary responsibility for evaluating business opportunities such as geographic expansion, joint ventures, partnerships and acquisitions. He works closely with all Porzio Life Sciences personnel to ensure the continuous improvement of the company's products and services and to maintain its leadership in the field of pharmaceutical sales and marketing compliance consulting.

Mr. Campbell received a J.D. from Stanford Law School and a B.A. from Dickinson College, where he graduated summa cum laude.

Catherine Arnold

Catherine Arnold

Assistant Director, Forensic Services practice, Deloitte

Catherine is an Assistant Director within the Forensic Services practice at Deloitte in London. She is a qualified Charted Accountant with over 8 years' experience in fraud and regulatory forensic investigations. Catherine has experience of conducting large global investigations into matters ranging from corruption, fraud, accounting irregularities and accounting misstatement, as well as advising companies with respect to their anti-fraud and corruption policies, procedures and controls.

Simon Airey

Simon Airey

Partner, DLA Piper

Simon Airey specialises in bribery, corruption, tax and fraud investigations and corporate compliance issues.

He is advising a large number of multinational groups in relation to their anti‑bribery and corruption programmes and has presented seminars all around the world in relation to the UK Bribery Act. At the invitation of the Chinese government, he recently presented a number of seminars to several hundred officials at China's largest governmental agency, the National Development & Reform Commission, in Beijing.

Simon was previously involved in the largest cartel case ever prosecuted by the Serious Fraud Office and he acted in one of the UK's most significant cases involving the supply of arms to Iraq in breach of sanctions and UK licensing laws. Both prosecutions were abandoned.

He is currently representing a major multinational in relation to an SFO bribery investigation and is supervising several other internal investigations. He is working with Transparency International to formulate guidance in relation to small bribes and 'facilitation payments'.

In recent years, he has advised around 50 financial institutions in relation to compulsory disclosure notices obtained against them by HMRC relating to offshore assets held by their clients. He is DLA Piper's Money Laundering Reporting Officer.

Huw Evans

Huw Evans

Partner, Norton Rose Fulbright

Huw Evans is a partner in the London office of Norton Rose. He joined Norton Rose in January 2013. He has over 20 years experience of assisting clients with intellectual property matters. Throughout his career, Huw has focused on dispute resolution involving the full range of intellectual property rights but with a particular emphasis on the life sciences sector. Much of his work is of a cross-border nature and in addition to litigation includes providing freedom to operate opinions and helping clients manage risk. Technical areas within the life sciences arena Huw has advised on include OTC diagnostic products and remote diagnostic systems, blood screening, immunoassay technology, blood filters, functional foods and the use of antibodies for targeted therapeutic products. Huw's first taste of life sciences litigation dates back to the very early 1990s when he was the lead associate for Murex Diagnostics in their defence against Chiron's claim for infringement in respect of their hepatitis C patents. More recently and while at his previous law firm Huw worked on the Pfizer v Teva (atorvastatin) case in which a preliminary injunction in respect of Pfizer's SPC was secured against Teva on the very day Teva launched generic atorvastatin and the MedImmune v Novartis case (Lucentis) where Novartis defeated MedImmune's claim that their screening tool patent was valid and infringed by Novartis' Lucentis product - this dispute also involved the first time an English judge applied CJEU's decision in Medeva as to how "specified in the wording of the claims" an active ingredient needs be to obtain an SPC.

Huw is recognised by Legal 500 and ranked by Chambers and IAM 1000.

Adam Cooke

Adam Cooke

Adam Cooke, Partner, IP, UK, DLA Piper

Adam Cooke is a partner in DLA Piper's Intellectual Property group in London. He has over 20 years' experience devoted to IP, focusing on multi-jurisdictional patent litigation especially in the life sciences and high technology sectors. His life sciences work frequently involves advising on the strategic interplay between patents on the one hand and regulatory data exclusivity on the other. He also advises on infringement and validity issues, including freedom to operate, as well as negotiating and drafting commercial IP agreements and advising on the IP aspects of corporate deals. His patent litigation experience includes patents relating to recombinant t-PA (first trial in the world concerning patentability of cDNA), insulin, hGH, insulin-like growth factor, anti-CD20 antibodies for the treatment of RA, diagnostic methods, medical devices (blood filters) and MRI scanners.

Adam is an elected board member of the UK IP Lawyers Association, IPLA, and is recognised as a leading patent lawyer by a number leading directories and guides including Chambers 2012 (IP), Chambers Global 2012 (IP), PLC Which Lawyer? 2012 (IP: patent litigation, and Life Sciences: patent litigation) and Intellectual Asset Management Patent 1000 - The World's Leading Patent Practitioners (2012).

John Dougherty

John Dougherty

John Dougherty, Partner, Global Co-Chair Life Sciences Sector, US, DLA Piper

As Co-Chair of DLA Piper's Life Sciences practice, John represents and advises some of the world's best known companies on complex multi-disciplinary litigation and other strategic challenges. His intellectual property litigation practice focuses on patent, trade secret and licensing litigation. John has tried cases in federal and state courts and has significant experience representing chemical and pharmaceutical companies in patent litigation. John represented a pharmaceutical company in a patent license dispute involving methods of producing recombinant DNA antibodies and regularly counsels clients on crisis management, litigation avoidance, and regulatory matters. John is highly experienced in leading and co-ordinating "virtual firms" drawn from multiple outside law firms, including designing best practices for managing multi-counsel teams and setting and supervising their multimillion-dollar budgets.


In house:

Valid until: 1 Attendee 2 Attendees 3 Attendees
10 February 2014 £1199 + VAT £2299 + VAT £2699 + VAT
Standard Price £1399 + VAT £2699 + VAT £3699 + VAT

Private Practice:

Valid until: 1 Attendee 2 Attendees
10 February 2014 £1499 + VAT £2699 + VAT
Standard price £1699 + VAT £3099 + VAT

Who should attend?

  • General Counsel.
  • In-house Counsel.
  • Directors/Heads of Legal.
  • Internal Compliance Professionals.
  • Lawyers in firms covering competition, corporate, IP, litigation, and regulatory.
  • Professionals in the life sciences, medical devices and biotech industries.

If you do not fall into these criteria but are still interested in attending please contact Kayta Kravtsova:

Attendance at the event is subject to the Practical Law Event terms and conditions.

Booking information

CALL: Richard Cooper +44 (0)20 34236396
E-MAIL: Richard.Cooper@practicallaw.com

Attendance at the event is subject to the Practical Law event terms and conditions.


Date: 4-5 MARCH 2014

Location: The Langham Hotel London

1c Portland Pl, London W1B 1JA, United Kingdom

Tel: +44 20 7636 1000

View Larger Map




Matheson’s primary focus is on serving the Irish legal needs of international companies and financial institutions doing business in and through Ireland.

Our Life Sciences Group advises organisations in the pharmaceutical, biotechnology, medical technology, agri-chem and healthcare sectors on the full range of legal issues that affect them. The group is structured on a cross-departmental basis, drawing specialist members from the firm's corporate, taxation, litigation, intellectual property, competition, commercial, environmental and property groups.

We are headquartered in Dublin and also have offices in London, New York and Palo Alto.

We offer a range of highly-tailored networking, research and branding opportunities at our events. Don’t miss the opportunity to develop your brand and expand your business network through our bespoke packages.

For more information on the opportunities and the benefits they can bring to your business, please contact Katya Kravtsova on: +44 (0) 20 7202 1200 or email Katya.Kravtsova@practicallaw.com.

Media partners



The WIPR Annual and its sister publications World IP Review (WIPR) and Trademarks, Brands and the Internet (TB&I) provide comprehensive guides to the challenges facing businesses and legal practitioners active in intellectual property, while IP Pages is the largest guide to law firms and service providers of its kind in the market. WIPR group covers all of the most important IP issues in the most important industries, looking at how companies protect their IP assets in a world which values IP more than it ever has.

Life Sciences IP Review

Life Sciences IP Review

The Life Sciences IP Review tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences From gene patents to stem cell research, we hope to provide the best news and analysis.



PharmaVOICE magazine, reaching more than 34,000 BPA-qualified life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE provides readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com provides a comprehensive directory of products, services, and solutions for the life-sciences industry.

To Raise Your VOICE, contact feedback@pharmavoice.com.

Technology Networks

Technology Networks

Founded in 2000, Technology Networks is now the leading provider of free information services for academics and industry professionals within the life science and drug discovery sectors. Our portfolio of 28 communities provides a base for members to access the latest news, events, products and research from their chosen field. All communities can be accessed through TechnologyNetworks.com.

Ark Patent Intelligence

Ark Patent Intelligence

If having comprehensive and relevant patent intelligence is important for your work, you might already use GenericsWeb Pipeline Patent Intelligence. Boasting 10 of the top 12 generic companies as clients and world renowned for insightful analysis as the benchmark in quality data, Pipeline Patent Intelligence has been reborn bigger and better under the new brand name Ark Patent Intelligence. Containing everything you already know and love from the previous model, Ark Patent Intelligence has a smarter user interface, key patent analysis and interpretation, increased country coverage and more. If you are interested in patent intelligence with unprecedented ease and reliability, please contact us through arkpatentintelligence.com.

If you are interested in becoming a media partner or would like more information on the opportunities we can offer for our events; please contact Rebecca Lock on: +44 (0)20 3423 6459 or email Rebecca.Lock@practicallaw.com.

Contact us

If you would like to know more about any event, please contact the events team or call +44 20 7202 1220.

Follow us

Follow our Events on Twitter.

{ "siteName" : "PLC", "objType" : "PLCWebPage", "objID" : "1247918030328", "objName" : "second-annual-life-sciences-law-forum", "userID" : "2", "objUrl" : "http://uk.practicallaw.com/cs/Satellite/resources/events/second-annual-life-sciences-law-forum?null", "pageType" : "Other", "academicUserID" : "", "contentAccessed" : "true", "analyticsPermCookie" : "2-62dceab2:15b04e1e8cd:-277b", "analyticsSessionCookie" : "2-62dceab2:15b04e1e8cd:-277a", "statisticSensorPath" : "http://analytics.practicallaw.com/sensor/statistic" }